ES2176574T3
(es)
|
1996-09-03 |
2002-12-01 |
Gsf Forschungszentrum Umwelt |
Utilizacion de anticuerpos bi y triespecificos para la induccion de inmunidad tumoral.
|
ES2169299T3
(es)
*
|
1996-09-03 |
2002-07-01 |
Gsf Forschungszentrum Umwelt |
Procedimiento para la destruccion de celulas tumorales contaminantes en transplantes de celulas madre utilizando anticuerpos especificos.
|
US6863887B1
(en)
*
|
1998-03-30 |
2005-03-08 |
Northwest Biotherapeutics, Inc. |
Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis
|
DK1068357T3
(da)
|
1998-03-30 |
2011-12-12 |
Northwest Biotherapeutics Inc |
Terapeutiske og diagnostiske anvendelser baseret på CXCR-4-genets rolle i tumorgenese
|
ES2267275T3
(es)
*
|
1998-07-10 |
2007-03-01 |
Connex Gmbh |
Reactivo inmunologico que interacciona especificamente con el dominio extracelular de la cadena zeta humana.
|
WO2000018806A1
(de)
*
|
1998-09-25 |
2000-04-06 |
Horst Lindhofer |
Bispezifische und trispezifische antikörper, die spezifisch mit induzierbaren oberflächenantigenen als operationelle zielstrukturen reagieren
|
JP4896327B2
(ja)
|
1999-08-23 |
2012-03-14 |
ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド |
Pd−1、b7−4の受容体、およびその使用
|
EP2388590A1
(en)
|
2001-04-02 |
2011-11-23 |
Dana Farber Cancer Institute |
PD-1, a receptor for B7-4, and uses thereof
|
AT502293B1
(de)
*
|
2002-05-15 |
2008-03-15 |
Igeneon Krebs Immuntherapie |
Immunogener, monoklonaler antikörper
|
US20040265315A1
(en)
*
|
2002-09-05 |
2004-12-30 |
Christine Dingivan |
Methods of preventing or treating T cell malignancies by administering CD2 antagonists
|
CA2502367C
(en)
|
2002-10-16 |
2013-12-10 |
Euro-Celtique S.A. |
Antibodies that bind cell-associated ca 125/o772p and methods of use thereof
|
AU2004225941A1
(en)
*
|
2003-03-28 |
2004-10-14 |
Elusys Therapeutics, Inc. |
Method and compositions for conversion of antibody activity
|
CA2524771A1
(en)
*
|
2003-05-09 |
2005-01-20 |
University Of Massachusetts |
Non-human animals expressing heterologous complement receptor type 1 (cr1) molecules on erythrocytes and uses therefor
|
JP2007510738A
(ja)
*
|
2003-11-06 |
2007-04-26 |
アイコス、コーポレーション |
CD11d(α−d)インテグリンに特異的に結合する組成物を使用した慢性疼痛を処置する方法
|
AU2004297988A1
(en)
*
|
2003-12-04 |
2005-06-23 |
Laboratoires Serono Sa |
Methods for identifying modulators of active KIT tyrosine kinase receptor
|
US20060263792A1
(en)
*
|
2004-10-29 |
2006-11-23 |
Elusys Therapeutics, Inc. |
Use of CR1-binding molecules in clearance and induction of immune responses
|
EP3623473A1
(en)
|
2005-03-31 |
2020-03-18 |
Chugai Seiyaku Kabushiki Kaisha |
Process for production of polypeptide by regulation of assembly
|
US9670269B2
(en)
|
2006-03-31 |
2017-06-06 |
Chugai Seiyaku Kabushiki Kaisha |
Methods of modifying antibodies for purification of bispecific antibodies
|
JP5624276B2
(ja)
|
2006-03-31 |
2014-11-12 |
中外製薬株式会社 |
抗体の血中動態を制御する方法
|
EP3689912A1
(en)
|
2007-09-26 |
2020-08-05 |
Chugai Seiyaku Kabushiki Kaisha |
Method of modifying isoelectric point of antibody via amino acid substitution in cdr
|
ES2566957T3
(es)
|
2007-09-26 |
2016-04-18 |
Chugai Seiyaku Kabushiki Kaisha |
Región constante de anticuerpo modificado
|
EP2050764A1
(en)
*
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Novel polyvalent bispecific antibody format and uses thereof
|
US8242247B2
(en)
*
|
2007-12-21 |
2012-08-14 |
Hoffmann-La Roche Inc. |
Bivalent, bispecific antibodies
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
ES2796085T3
(es)
|
2008-01-15 |
2020-11-25 |
Univ Leland Stanford Junior |
Marcadores de células madre de leucemia mieloide aguda
|
MX349463B
(es)
|
2008-09-26 |
2017-07-31 |
Univ Emory |
Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos.
|
CN102448494B
(zh)
|
2009-02-13 |
2016-02-03 |
免疫医疗公司 |
具有胞内可裂解的键的免疫共轭物
|
JP5717624B2
(ja)
|
2009-03-19 |
2015-05-13 |
中外製薬株式会社 |
抗体定常領域改変体
|
TWI682995B
(zh)
|
2009-03-19 |
2020-01-21 |
日商中外製藥股份有限公司 |
抗體恆定區域改變體
|
MX2011010159A
(es)
|
2009-04-02 |
2011-10-17 |
Roche Glycart Ag |
Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla.
|
JP5616428B2
(ja)
|
2009-04-07 |
2014-10-29 |
ロシュ グリクアート アクチェンゲゼルシャフト |
三価の二重特異性抗体
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
US8758750B2
(en)
|
2009-09-15 |
2014-06-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Synergistic anti-CD47 therapy for hematologic cancers
|
CA2774260C
(en)
|
2009-09-16 |
2018-10-09 |
Immunomedics, Inc. |
Class i anti-cea antibodies and uses thereof
|
WO2011034605A2
(en)
|
2009-09-16 |
2011-03-24 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
JP5837821B2
(ja)
|
2009-09-24 |
2015-12-24 |
中外製薬株式会社 |
抗体定常領域改変体
|
CA2778953C
(en)
|
2009-11-13 |
2020-01-14 |
Dana-Farber Cancer Institute, Inc. |
Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
|
EP2506876B1
(en)
*
|
2009-12-02 |
2016-10-12 |
Imaginab, Inc. |
J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
|
CA2782194C
(en)
|
2009-12-02 |
2018-01-16 |
Immunomedics, Inc. |
Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer
|
CN102791738B
(zh)
|
2009-12-10 |
2015-10-07 |
霍夫曼-拉罗奇有限公司 |
优先结合人csf1r胞外域4的抗体及其用途
|
MX2012007497A
(es)
*
|
2009-12-25 |
2012-08-01 |
Chugai Pharmaceutical Co Ltd |
Metodo para modificacion de polipeptidos para purificar multimeros de polipeptido.
|
JP5889181B2
(ja)
|
2010-03-04 |
2016-03-22 |
中外製薬株式会社 |
抗体定常領域改変体
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
WO2011133886A2
(en)
*
|
2010-04-23 |
2011-10-27 |
Genentech, Inc. |
Production of heteromultimeric proteins
|
CN103068846B9
(zh)
|
2010-08-24 |
2016-09-28 |
弗·哈夫曼-拉罗切有限公司 |
包含二硫键稳定性Fv片段的双特异性抗体
|
MX355060B
(es)
|
2010-11-17 |
2018-04-03 |
Chugai Pharmaceutical Co Ltd |
Molecula multiespecifica de union a antigeno que tiene funcion alternativa a la funcion del factor viii de coagulacion sanguinea.
|
CN103429737B
(zh)
|
2010-11-30 |
2020-07-14 |
中外制药株式会社 |
细胞毒诱导治疗剂
|
WO2012085111A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
WO2012116926A1
(en)
|
2011-02-28 |
2012-09-07 |
F. Hoffmann-La Roche Ag |
Antigen binding proteins
|
AR085403A1
(es)
|
2011-02-28 |
2013-09-25 |
Hoffmann La Roche |
Proteinas monovalentes que se unen a antigenos
|
TWI588156B
(zh)
*
|
2011-03-28 |
2017-06-21 |
賽諾菲公司 |
具有交叉結合區定向之雙重可變區類抗體結合蛋白
|
JP6024025B2
(ja)
|
2011-05-02 |
2016-11-09 |
イミューノメディクス、インコーポレイテッドImmunomedics, Inc. |
少容量投与用のアロタイプ選択抗体の限外濾過濃縮
|
KR102106002B1
(ko)
|
2011-10-11 |
2020-05-07 |
제넨테크, 인크. |
이중특이적 항체의 개선된 어셈블리
|
US10023643B2
(en)
|
2011-12-15 |
2018-07-17 |
Hoffmann-La Roche Inc. |
Antibodies against human CSF-1R and uses thereof
|
RU2644341C2
(ru)
|
2012-02-10 |
2018-02-08 |
Дженентек, Инк. |
Одноцепочечные антитела и другие гетеромультимеры
|
CA2871882A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
|
EP2867253B1
(en)
|
2012-06-27 |
2016-09-14 |
F. Hoffmann-La Roche AG |
Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
|
ES2771324T3
(es)
|
2012-08-03 |
2020-07-06 |
Dana Farber Cancer Inst Inc |
Usos médicos de agentes que modulan la activación de las células inmunitarias y métodos de detección correspondientes
|
CA2874864C
(en)
|
2012-08-14 |
2023-02-21 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
WO2017004144A1
(en)
|
2015-07-01 |
2017-01-05 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
PL2900277T3
(pl)
|
2012-12-13 |
2022-05-16 |
Immunomedics, Inc. |
Dawkowanie immunokoniugatów przeciwciał i sn-38 dla poprawy skuteczności i zmniejszenia toksyczności
|
AU2014275166B2
(en)
|
2013-06-06 |
2020-09-10 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identification, assessment prevention, and treatment of cancer using PD-L1 isoforms
|
WO2015017529A2
(en)
|
2013-07-31 |
2015-02-05 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules
|
AR097584A1
(es)
|
2013-09-12 |
2016-03-23 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
|
EP3049442A4
(en)
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
DK3050896T3
(da)
|
2013-09-27 |
2021-07-19 |
Chugai Pharmaceutical Co Ltd |
Fremgangsmåde til fremstilling af en polypeptid-heteromultimer
|
CA2922912A1
(en)
|
2013-10-11 |
2015-04-16 |
F. Hoffmann-La Roche Ag |
Multispecific domain exchanged common variable light chain antibodies
|
WO2015095868A1
(en)
|
2013-12-20 |
2015-06-25 |
Wake Forest University Health Sciences |
Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
|
WO2015105995A2
(en)
|
2014-01-08 |
2015-07-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Targeted therapy for small cell lung cancer
|
CA2935804A1
(en)
|
2014-01-14 |
2015-07-23 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
|
WO2015126548A1
(en)
|
2014-02-21 |
2015-08-27 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to trop-2 expressing cells
|
WO2015130416A1
(en)
|
2014-02-25 |
2015-09-03 |
Immunomedics, Inc. |
Humanized rfb4 anti-cd22 antibody
|
EP3560954B1
(en)
|
2014-04-03 |
2021-08-04 |
IGM Biosciences, Inc. |
Modified j-chain
|
EP2930188A1
(en)
*
|
2014-04-13 |
2015-10-14 |
Affimed Therapeutics AG |
Trifunctional antigen-binding molecule
|
RU2718692C2
(ru)
|
2014-05-29 |
2020-04-13 |
Мэкроудженикс, Инк. |
Триспецифичные связывающие молекулы, которые специфически связывают антигены множества злокачественных опухолей, и способы их применения
|
GB201409558D0
(en)
|
2014-05-29 |
2014-07-16 |
Ucb Biopharma Sprl |
Method
|
CA2953567C
(en)
|
2014-06-24 |
2023-09-05 |
Immunomedics, Inc. |
Anti-histone therapy for vascular necrosis in severe glomerulonephritis
|
GB201412658D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
GB201412659D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
CN106999517A
(zh)
|
2014-10-07 |
2017-08-01 |
免疫医疗公司 |
抗体‑药物缀合物的新辅助剂用途
|
CN107001482B
(zh)
|
2014-12-03 |
2021-06-15 |
豪夫迈·罗氏有限公司 |
多特异性抗体
|
WO2016094273A1
(en)
|
2014-12-08 |
2016-06-16 |
Dana-Farber Cancer Institute, Inc. |
Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents
|
BR112017018941B8
(pt)
|
2015-03-04 |
2023-01-10 |
Igm Biosciences Inc |
Molécula de ligação a cd20, seu uso, composição e método in vitro para direcionar a morte mediada por complemento de uma célula que expressa cd20
|
AU2016232749B2
(en)
|
2015-03-18 |
2021-09-23 |
The Johns Hopkins University |
Novel monoclonal antibody inhibitors targeting potassium channel KCNK9
|
WO2016159213A1
(ja)
|
2015-04-01 |
2016-10-06 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
JP6746845B2
(ja)
|
2015-04-22 |
2020-08-26 |
イミューノメディクス、インコーポレイテッドImmunomedics, Inc. |
循環trop−2陽性癌細胞の単離、検出、診断及び/または特徴付け
|
CN107735104B
(zh)
|
2015-06-25 |
2022-05-03 |
免疫医疗公司 |
组合抗hla-dr抗体或抗trop-2抗体与微管抑制剂、parp抑制剂、布鲁顿激酶抑制剂或磷酸肌醇3-激酶抑制剂使癌症治疗结果显著改善
|
GB201601075D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies molecules
|
GB201601073D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies
|
GB201601077D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibody molecule
|
CN108463245A
(zh)
|
2015-09-30 |
2018-08-28 |
Igm生物科学有限公司 |
具有修饰的j链的结合分子
|
EP3356401B1
(en)
|
2015-09-30 |
2020-06-24 |
IGM Biosciences, Inc. |
Binding molecules with modified j-chain
|
WO2017066561A2
(en)
|
2015-10-16 |
2017-04-20 |
President And Fellows Of Harvard College |
Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
|
GB201521383D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl And Ucb Celltech |
Method
|
GB201521389D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Method
|
GB201521393D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
GB201521391D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
GB201521382D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
JP7219005B2
(ja)
|
2015-12-28 |
2023-02-07 |
中外製薬株式会社 |
Fc領域含有ポリペプチドの精製を効率化するための方法
|
US20210309965A1
(en)
|
2016-03-21 |
2021-10-07 |
Dana-Farber Cancer Institute, Inc. |
T-cell exhaustion state-specific gene expression regulators and uses thereof
|
EP3504239B1
(en)
|
2016-08-25 |
2024-05-29 |
F. Hoffmann-La Roche AG |
Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
|
WO2018112032A1
(en)
|
2016-12-13 |
2018-06-21 |
President And Fellows Of Harvard College |
Methods and compositions for targeting tumor-infiltrating tregs using inhibitors of ccr8 and tnfrsf8
|
EP3558360A1
(en)
|
2016-12-22 |
2019-10-30 |
F. Hoffmann-La Roche AG |
Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
|
RU2663104C1
(ru)
*
|
2017-07-13 |
2018-08-01 |
Общество с ограниченной ответственностью "Реал Таргет" |
Получение пегилированных фрагментов gd2-специфичных антител, индуцирующих прямую клеточную гибель gd2-позитивных опухолевых клеток, и их применение в терапии gd2-позитивных опухолей
|
EP3962529A4
(en)
|
2019-04-30 |
2023-11-01 |
Dana-Farber Cancer Institute, Inc. |
METHOD FOR CANCER TREATMENT USING ANTI-CX3CR1 AND IMMUNE CHECKPOINT BLOCKING REAGENTS COMBINATIONS
|
EP4342497A1
(en)
|
2021-05-10 |
2024-03-27 |
Kawasaki Institute of Industrial Promotion |
Antibody having reduced binding affinity for antigen
|
WO2022261183A2
(en)
|
2021-06-08 |
2022-12-15 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
|
WO2023097119A2
(en)
|
2021-11-29 |
2023-06-01 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions to modulate riok2
|
WO2023201226A1
(en)
|
2022-04-11 |
2023-10-19 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for universal tumor cell killing
|
WO2024059183A1
(en)
|
2022-09-14 |
2024-03-21 |
President And Fellows Of Harvard College |
Methods and compositions for modulation of piezo1 in the treatment of cancer
|